Rapid Dose Announces Payment in Shares for Quarterly Interest on Secured Debt

• On April 6 2026 Rapid Dose Therapeutics announced it will issue 1,263,001 common shares to satisfy $138,931.71 of accrued interest on its amended and restated secured convertible notes (dated Dec 1 2025).
• The deemed issue price is $0.11 per share (CSE closing price on March 31 2026); shares are expected to be delivered no later than April 15 2026 and will be subject to a four‑month‑plus‑one‑day hold period (expiring early August 2026).
• The notes bear 18% interest per annum, compounded monthly, with quarterly interest payable in common shares. Maturity of the $3,084,445 of promissory notes was previously extended to November 30 2026; associated warrants (15,422,225) were likewise extended to that date with an exercise price of $0.16.
• The company retains the right to prepay the notes with ten days’ notice without additional premium or bonus.

• The announcement follows the exact mechanics already disclosed in prior quarterly interest‑payment releases (e.g., Jan 5 2026 and Oct 2 2025).
• No new information regarding the underlying debt terms, maturity date, or conversion price is introduced; the share issuance size is consistent with the 18% coupon applied to the outstanding principal.
• Consequently, the news does not alter the company’s fundamental outlook beyond the anticipated dilution that has been recurring each quarter. It represents an expected, routine event rather than a material surprise.

Rapid Dose Therapeutics Corp. (CSE: DOSE; OTCQB: RDTCF) develops the QuickStrip™ oral thin‑film delivery platform for rapid, discreet absorption of active ingredients. Its flagship products include: - QuickStrip™ medical cannabis – launched in Brazil following ANVISA approval (Feb 2026), targeting chronic pain, anxiety, sleep disorders, etc., via sublingual/buccal absorption.
- QuickStrip™ nicotine bilayer oral film – covered by an Indian patent (IN 582202, granted Mar 2026) and positioned for the fast‑growing smoke‑free nicotine market (~$38.9 bn projected by 2033).
- CBD bioavailability study – funded by the NFL, evaluating QuickStrip™ as a superior delivery route for cannabidiol in sports‑related concussion research. The company’s strategy centers on expanding regulated international markets (Brazil, India, North America), strengthening distribution channels for natural health products, advancing clinical validation across nicotine, cannabis and CBD verticals, and scaling Canadian manufacturing to pharmaceutical‑grade capacity.